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Since case deﬁnitions for tuberculous meningitis (TBM) differ
among research groups, an expert panel meeting proposed a set of
consensus deﬁnitions for diagnosis and a scoring system.1 The
scoring system1 comprises four parts, and points are given for
variables that are present. Patients are judged to have deﬁnite TBM
if Mycobacterium tuberculosis is identiﬁed in the cerebrospinal ﬂuid
(CSF). Patients have probable TBM if they score at least 10/12
points with/without cerebral imaging results, and have possible
TBM if they have a diagnostic score of 6–9 when cerebral imaging is
available, or 6–11 points without cerebral imaging (Table 1).
We retrospectively studied patients hospitalized in our
infectious diseases facility between January 2001 and January
2011 with a positive CSF culture for M. tuberculosis (46 patients),
positive commercial nucleic acid ampliﬁcation test results (seven
patients), or both tests positive (two patients). We compared our
deﬁnite TBM patients against the three categories of TBM and non-
TBM as deﬁned above. Our study was conducted in a population
with a relatively high incidence of tuberculosis, with a notiﬁcation
rate of 115.1 per 100 000 population.2
Fifty-ﬁve patients with conﬁrmed TBM were identiﬁed; their
median age was 34 years (range 2–78 years) and seven patients
were under 14 years of age. By the consensus deﬁnitions, 26 (47%)Table 1
Characteristics of patients with conﬁrmed tuberculous meningitis
Clinical criteria 
Symptom duration of more than 5 days 
Systemic symptoms (weight loss, night sweats, persistent cough >2 weeks) 
History of recent close contact with an individual with pulmonary tuberculosis 
Focal neurological deﬁcits 
Cranial nerve palsy 
Altered consciousness 
CSF criteria 
Clear appearance 
Cells 50–500  106/l 
Lymphocyte predominance (>50%); N = 40 
Protein concentration >1 g/l 
CSF to plasma glucose ratio <50, or CSF glucose <2.2 mmol/l 
Cerebral imaging criteria 
Hydrocephalus 
Basal meningeal enhancement 
Tuberculoma 
Infarct 
Evidence of tuberculosis elsewhere 
Chest X-ray suggestive of active TB/miliary TB 
CT/MRI/ultrasound evidence of TB outside the CNS 
Acid-fast bacilli identiﬁed or M. tuberculosis cultured from another source 
Positive NAAT for M. tuberculosis from extra-neural specimen 
CSF, cerebrospinal ﬂuid; TB, tuberculosis; CT, computed tomography; MRI, magnetic reso
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possible TBM. Interestingly, four (7%) patients with proven TBM
could not be classiﬁed as having probable or possible TBM applying
the scoring system, having scored less than 6 points.
The main limitation of our study was its retrospective nature,
with missing data for mononuclear predominance in 15 patients
and central nervous system imaging in 20 patients. Eight patients
without data on CSF mononuclear predominance were classiﬁed as
probable TBM and six as possible TBM, and only one could not be
classiﬁed as TBM. Imaging studies had not been performed in seven
of 25 patients classiﬁed as possible TBM and three of four patients
classiﬁed as non-TBM. The need for cerebral computed tomogra-
phy or magnetic resonance imaging as part of the classiﬁcation
must be highlighted, since patients with an incomplete evaluation
might be misclassiﬁed. Nevertheless, one patient with proven
TBM, with available cerebral imaging results and data on CSF
mononuclear predominance, would still have been misclassiﬁed as
non-TBM applying this scoring system.
For conﬁrmed TBM cases in our study, 93% of patients would
have been classiﬁed as having probable and possible TBM.
Therefore speciﬁc treatment would need to be considered in
these patients if the scoring system were to be used in a clinical
setting. Diagnosing TBM is crucial due to the high mortality and
signiﬁcant morbidity associated with delayed treatment.3 The
proposed TBM case deﬁnition is a valuable tool, not only forMaximum score = 6 N = 55, n (%)
4 45 (82)
2 28 (51)
2 1 (2)
1 15 (27)
1 16 (29)
1 40 (73)
Maximum score = 4 N = 55, n (%)
1 55 (100)
1 43 (78)
1 36 (90)
1 46 (84)
1 49 (89)
Maximum score = 6 N = 35, n (%)
1 19 (54)
2 3 (9)
2 2 (6)
1 12 (34)
Maximum score = 4 N = 55, n (%)
2/4 23 (42)/4 (7)
2 6 (11)
4 4 (7)
4 0 (0)
nance imaging; CNS, central nervous system; NAAT, nucleic acid ampliﬁcation test.
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applied carefully.
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